MYL - Mylan N.V.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
17.19
-1.49 (-7.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close18.68
Open17.82
Bid17.41 x 2900
Ask17.50 x 3100
Day's range16.57 - 18.06
52-week range16.57 - 29.30
Volume16,177,256
Avg. volume6,166,190
Market cap8.873B
Beta (5Y monthly)N/A
PE ratio (TTM)573.00
EPS (TTM)0.03
Earnings date04 May 2020 - 10 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend date26 Jun 2007
1y target est25.00
  • Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates
    Zacks

    Mylan's (MYL) Q4 Earnings Beat, Revenues Miss Estimates

    Mylan's (MYL) earnings beat estimates but sales miss the same in the fourth quarter of 2019.

  • Mylan (MYL) Tops Q4 Earnings Estimates
    Zacks

    Mylan (MYL) Tops Q4 Earnings Estimates

    Mylan (MYL) delivered earnings and revenue surprises of 8.53% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Mylan warns of possible drug shortages, financial hit due to coronavirus
    Reuters

    Mylan warns of possible drug shortages, financial hit due to coronavirus

    The outbreak has so far mainly battered China, causing nearly 80,000 infections and more than 2,700 deaths, according to World Health Organization figures. Mylan said it was facing logistical issues, but had not seen problems with production or experienced price increases in active drug ingredients. Although heavily reliant on China, the company said it was better positioned against the impact of the outbreak compared to its peers due to its diversified supply chain.

  • Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat
    Zacks

    Momenta's (MNTA) Q4 Loss Wider than Expected, Sales Beat

    Momenta (MNTA) reports mixed Q4 results, with a wider-than-expected loss and revenues beating the same.

  • Mylan Earnings Beat, Revenue Misses In Q4
    Investing.com

    Mylan Earnings Beat, Revenue Misses In Q4

    Investing.com - Mylan (NASDAQ:MYL) reported on Thursday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

  • Business Wire

    Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

    Mylan N.V. (NASDAQ: MYL) and Pfizer (NYSE: PFE) today announced that Sanjeev Narula, current chief financial officer (CFO) of Upjohn, a division of Pfizer, has been named incoming CFO of Viatris, the new company that will result from the planned combination of Mylan and Upjohn. Upon closing, which is expected in mid-2020, Viatris will be a new champion for global health with a portfolio of approximately 3,000 brands and molecules and a commercial presence in 165 countries.

  • Business Wire

    Mylan and Pfizer Finalize Appointments to Viatris Board of Directors

    Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced the remaining appointees to the inaugural 13-member Board of Directors for Viatris, the new company that will result from the combination of Mylan and Upjohn, a division of Pfizer, which is expected to occur in mid-2020, subject to receipt of regulatory approvals, Mylan shareholder approval, and the satisfaction of other customary closing conditions. In addition to the previously announced Pfizer-designated appointments of Ian Read and Jim Kilts, Pfizer has appointed current Pfizer board member W. Don Cornwell, who will resign from the Pfizer board to serve as a director of Viatris upon the close of the transaction. Additionally, Mylan has appointed eight of its own directors to serve on the Viatris Board of Directors, including JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish and Pauline van der Meer Mohr. As previously announced, the Board of Directors of Viatris will also include Viatris Executive Chairman Robert J. Coury and Viatris CEO Michael Goettler.

  • Is a Surprise Coming for Mylan (MYL) This Earnings Season?
    Zacks

    Is a Surprise Coming for Mylan (MYL) This Earnings Season?

    Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates
    Zacks

    Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates

    Theravance (TBPH) reports earnings miss in the fourth quarter while sales beat estimates.

  • The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
    Zacks

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

    The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries

  • 3 Best Drugmakers That Are Immune to Coronavirus Fright
    Zacks

    3 Best Drugmakers That Are Immune to Coronavirus Fright

    The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.

  • Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?
    Zacks

    Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?

    Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Mylan (MYL) to Report Q4 Earnings: What's in the Offing?
    Zacks

    Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

    Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.

  • Teva (TEVA) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

    Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

  • Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan
    Zacks

    Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan

    The U.S. Patent and Trademark Office imparts a ruling in favor of Biogen (BIIB) over generic drugmaker Mylan to protect the patent of its best-selling multiple sclerosis drug, Tecfidera.

  • Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down
    Zacks

    Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down

    Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.

  • Theravance Pipeline Strong, Dependence on Yupelri a Concern
    Zacks

    Theravance Pipeline Strong, Dependence on Yupelri a Concern

    Theravance's (TBPH) COPD drug Yupelri witnesses a strong adoption while its pipeline programs make a steady progress. However, high reliance on Yupelri for revenues is a concern.

  • Biogen Investors Face Next Test With Pending Drug Patent Ruling
    Bloomberg

    Biogen Investors Face Next Test With Pending Drug Patent Ruling

    (Bloomberg) -- Biogen Inc. investors should strap themselves in for a volatile week ahead of a key patent decision on its blockbuster multiple sclerosis drug.A decision from the U.S. Patent Trial and Appeal Board, expected by February 6, could move shares up or down by 8%, options expiring February 7 show. Implied volatility is elevated near 70%, which compares to a three-month historical average of 46%.Competitor Mylan NV is challenging a patent on the drug, Tecfidera, that could wipe out eight years of exclusivity for Biogen and bring a copycat drug to patients sooner than hoped. SunTrust analyst Robyn Karnauskas said a negative outcome for Biogen could slash the biotech’s discounted cash flow model by $40 per share, though specifics on Mylan’s commercial efforts are key to assessing the damage.The drug brought in $1.16 billion in sales for the final three months of 2019, with full-year revenue from the drug reaching $4.4 billion, roughly 30% of the company’s revenue. While bears have pointed out that a negative decision could impact sales in the near-term, William Blair analysts highlighted in a note to clients that any decision will likely be appealed, delaying a final ruling.Chief Financial Officer Jeff Capello told analysts Jan. 30 that the company would appeal any loss in either the patent office or district court cases, which would take 12 to 18 months. Capello said it is “difficult to predict” whether the generic-drug makers would launch without waiting for the appeals court decision.Decisions around Tecfidera patents “could provide near-term volatility and are extremely difficult to predict,” BMO Capital Markets analyst George Farmer wrote to clients. “Transitioning Tecfidera patients and initiating new patients to Vumerity, a more tolerable fumarate, would lessen the impact of a negative IPR decision, but the launch is too early to gauge demand.”Jefferies’ Michael Yee sees a bit more on the line for the decision, projecting a 10% move to either side for Biogen stock. He pointed out in a January 30 note that bears see Biogen as uninvestable ahead of the decision with bulls saying the ruling will remove an overhang on the stock.Among Biogen’s biggest fans on Wall Street, SVB Leerink, reiterated its outperform rating Monday morning writing that the current “valuation already reflects a worst case scenario for the Tecfidera loss of exclusivity.”The decision will pave the way for investors to bet on whether or not U.S. regulators will approve the company’s controversial Alzheimer’s drug candidate. Matt Phipps, an analyst at William Blair, highlighted that the patent ruling and the next steps for aducanumab are among the primary focuses for investors. Biogen is on pace to deliver a filing for the Alzheimer’s candidate sometime in the next two months.\--With assistance from Gregory Calderone, Susan Decker and Christopher Yasiejko.To contact the reporter on this story: Bailey Lipschultz in New York at blipschultz@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Steven Fromm, Cristin FlanaganFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down
    Zacks

    Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down

    Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.

  • Why the Earnings Surprise Streak Could Continue for Mylan (MYL)
    Zacks

    Why the Earnings Surprise Streak Could Continue for Mylan (MYL)

    Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Should Value Investors Buy Mylan (MYL) Stock?
    Zacks

    Should Value Investors Buy Mylan (MYL) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Top Ranked Value Stocks to Buy for January 27th
    Zacks

    Top Ranked Value Stocks to Buy for January 27th

    Top Ranked Value Stocks to Buy for January 27th

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more